Comparative Pharmacology
Head-to-head clinical analysis: ALPHADERM versus CARMOL HC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHADERM versus CARMOL HC.
ALPHADERM vs CARMOL HC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alpha-1 adrenergic receptor antagonist; blocks vasoconstriction and relaxes smooth muscle in blood vessels and prostate.
Carmol HC is a combination of urea (a keratolytic) and hydrocortisone (a corticosteroid). Urea softens and dissolves the intercellular matrix of the stratum corneum, promoting desquamation and enhancing penetration of hydrocortisone. Hydrocortisone suppresses inflammation by induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Topical: Apply a thin film to affected areas once daily. Not for ophthalmic, oral, or intravaginal use.
Apply a thin film to affected area twice daily; topical, not for ophthalmic or oral use.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min).
1-2 hours (hydrocortisone acetate); clinical effects persist longer due to local anti-inflammatory action; tissue half-life not well defined.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; less than 10% metabolized hepatically.
Primarily renal excretion of metabolites (40-60%) as glucuronide and sulfate conjugates; <10% unchanged; biliary/fecal elimination accounts for <20%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid